Reference | Drug | RA duration | Activity at Discontinuation | Number discontinued/continued | Follow-up (weeks) | DAS28 < 3.2 at end (%) | DAS28 < 2.6 at end (%) | SDAI ≤ 3.3 at end (%) | |||
---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  |  | Discontinued | Continued | Discontinued | Continued | Discontinued | Continued |
Double-blind controlled trials | |||||||||||
 Van Vollenhoven 2016 [44] | ETA | Est | DAS28-ESR ≤ 3.2 for ≥ 11 months | 23/23 | 48 | 13.0 | 52.1 | - | - | - | - |
 Emery 2020 [45] | ADA | Est | DAS28-ESR < 2.6 for ≥ 6 months | 20/102 | 36 | - | - | 57.8 | 62.7 | - | - |
 Curtis 2021 [46] | ETA | Est | SDAI ≤ 3.3 for 24 weeks | 101/51 | 48 | - | - | - | - | 28.7 | 52.9 |
Open-label trials | |||||||||||
 Chatzidionysiou 2016 [47] | ADA | Est | DAS28 < 2.6 ≥ 3 months | 15/16 | 28 | - | - | 33.3 | 93.7 | - | - |
 Ghiti Moghadam 2016 [48] | ETA 40% ADA 51% INF 5% | Est | DAS28-ESR < 3.2 ≥ 6 months | 531/286 | 52 | 48.8 | 81.8 | 29.7 | 56.9 | - | - |
Observational studies | |||||||||||
 Brocq 2009 [49] | ETA 65% ADA 25% INF 10% | Est | DAS28 < 2.6 for ≥ 6 months | 21/- | 52 | 25.0 | - | - | - | - | - |
 Tanaka RRR 2010 [50] | INF | Est | DAS28-ESR < 3.2 for ≥ 6 months | 102/- | 52 | 54.9 | - | 43.1 | - | - | - |
 Saleem 2010 [33] | ETA 25% ADA 10% INF 65% | Est | DAS28 < 2.6 for ≥ 6 months | 20/- | 96 | - | - | 15.0 | - | - | - |
 Iwamoto 2014 [51] | ETA 9% ADA 19% INF 53% GOL 15% CTZ 3% | Est | DAS28 < 2.6 (no duration specified) | 32/- | 24 | 59.3 | - | - | - | - | - |
 Kurasawa 2014 [52] | INF | Est | DAS28-CRP < 2.6 for ≥ 6 months | 31/- | 52 | - | - | 55.0 | - | - | - |
 Kadar 2014 [53] | TNFi | Est | Long-term remission | 5/- | 24 | - | - | 100 | - | - | - |
 Kavanaugh 2015 [54] | TNFi | Est | CDAI ≤ 10 (no duration specified) | 717/- | 52 | 73.4a | - |  | - | - | - |
 Yoshida 2016 [55] | Biologics (82% TNFi) | Est | CDAI ≤ 2.8 | 46/- | 52 | 32.6a | - | - | - | - | - |
 Kawashiri 2017 [56] | ETA 10% ADA 23% INF 47% GOL 13% CTZ 7% | Est | DAS28-ESR < 3.2 for ≥ 3 months | 30/- | 52 | 46.6a | - | - | - | - | - |
 Kimura 2019 [57] | ADA | Est | DAS28-ESR < 2.6 for ≥ 6 months | 4/29 | 52 | - | - | 25.0 | 75.8 | - | - |
 Ito 2019 [58] | ADA | Est | Sustained clinical remission | 20/- | 24 | 100 | - | 95 | - | - | - |
 Naniwa 2020 [59] | ETA 28% ADA 16% INF 47% GOL 3% CTZ 5% | Early | SDAI ≤ 11, off corticosteroids for ≥ 6 months | 95/- | 52 | - | - | 66.2 | - | 63.8 | - |
 Takai 2020 [60] | INF | Est | DAS28-ESR < 2.6, usually > 2 years | 18/- | 48 | 55.6 | - | 55.6 | - | - | - |
 Kameda 2021 [61] | ETA 38% ADA 12% INF 23% GOL 19% CTZ 8% | Est | SDAI ≤ 3.3 for ≥ 3 months | 26/- | 52 | 46.1 | - | - | - | - | - |
 Ochiai 2021 [62] | ETA 23% ADA 10% INF 67% | Est | DAS28-ESR < 3.2 (no duration reported) | 39/- | 52 | 56.4 | - | - | - | - | - |
 Burkard 2021 [63] | ETA 28% ADA 40% INF 12% GOL 13% CTZ 7% | Est | DAS28 < 2.6 or RADAI < 1.5 | 212/- | 104 | 30.7a | - | - | - | - | - |
 Nagatani 2021 [64] | ETA 50% ADA 12% INF 38% | Est | DAS28-CRP < 2.3 for ≥ 12 months | 34/- | 104 | - | - | 38.2 | - | - | - |